Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
Price : $35 *
At a glance
- Drugs RO 6924963 (Primary) ; RO 6931643 (Primary) ; RO 6958948 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use; Pharmacokinetics
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 04 May 2016 Status changed from active, no longer recruiting to completed.
- 02 Apr 2016 Planned End Date changed from 1 Oct 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.